Here are the highlights:
- 10 of 11 drugs that enter Phase 1 (91%) fail to achieve FDA approval. Of course this doesn't count all the of failed candidates that companies brag about cell culture or mouse experiment success with.
- The odds are better for the first attempted indication (1 in 7) than the secondary expanded indications (1 in 30)...prime example that comes to mind is Sutent from $PFE
- Large molecule drugs (monoclonal antibodies for example) succeed at twice the rate as small molecule drugs